title: Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
authors.forename: Paolo
authors.initials: P
authors.lastname: Manzoni
authors.forename: MariaLisa
authors.initials: M
authors.lastname: Leonessa
authors.forename: Daniele
authors.initials: D
authors.lastname: Farina
authors.forename: Giovanna
authors.initials: G
authors.lastname: Gomirato
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007153:Immunologic Deficiency Syndromes / Q000150:complications* / Q000276:immunology; D015994:Incidence; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal; D007558:Italy / Q000453:epidemiology; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab